Small Molecules
15 September 2017
CHMP Positive Opinion for Opioid Dependence Treatment With Zubsolv® (buprenorphine and naloxone) in Europe15 September 2017
TESARO Receives Positive CHMP Opinion for ZEJULA®15 September 2017
Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD15 September 2017
Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism15 September 2017
Vanda’s Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis15 September 2017
Santhera Receives Negative Opinion from the CHMP for its Marketing Authorization Application for Raxone® in DMD and Intends to Appeal this Opinion15 September 2017
New indication for BRIVIACT® (brivaracetam): UCB’s newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults14 September 2017
Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis14 September 2017
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell Disease14 September 2017
Phrixus Pharmaceuticals announces Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy14 September 2017
S-033188 Phase 3 CAPSTONE-1 Study Results for Treatment of Influenza Presented at the European Scientific Working Group on Influenza Conference13 September 2017
Amicus Therapeutics Announces Top-Line Phase 3 Results for SD-101 in Epidermolysis Bullosa13 September 2017
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma13 September 2017
GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence12 September 2017
Merck Advances Immunology Pipeline with Evobrutinib (Bruton’s Tyrosine Kinase Inhibitor)12 September 2017
Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus11 September 2017
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)11 September 2017
Lycera Presents Encouraging Safety Results from Phase 1 ARGON Study of LYC-55716 at the European Society for Medical Oncology (ESMO) Congress11 September 2017
Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 201711 September 2017
Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 201711 September 2017
Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract InfectionsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports